Tevogen Bio Holdings Inc. TVGN
6.00 USD +0.28 (+4.90%)
At closeNov 11, 2026, 4:00 PM EST
5.92 -0.08 -1.33%
After hours · Nov 11, 4:00 PM ET
5.99 Day range 6.00
3.64 52-week range 24.90
- YTD
- -63.75%
- 1 year
- -74.47%
News
globenewswire.com Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement Tevogen secures two extra years of capital access, with up to $28.6 million in borrowing capacity through May 2029, complementing its existing ATM program.
benzinga.com Tevogen Signs Letter Of Intent To Evaluate A Potential Transaction With HRK Healthcare; Sees Path To Realizing ~$100M In Combined Annual Revenue Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and
benzinga.com Tevogen To Operate Under Tevogen Inc. Name, Effective July 30 Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Directors. The name change…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
benzinga.com Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate Tevogen Bio Holdings (NASDAQ:TVGN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.50) by 35.6 percent. This is a 50.46 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Tevogen Enters $3M Private Placement PIPE Financing At $8.00/Prefunded Warrant, Issuing 375K Warrants Each Exercisable For The Purchase Of 1 Share Of The Company's Common Stock Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the "PIPE")…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Tevogen Bio Eyes Acquisition Of Global CRO To Add $20M+ Revenue And Fuel Growth Across Oncology, Rare Diseases, And Medical Devices Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates…- benzinga.com Tevogen Bio Regains Nasdaq Compliance Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the Company that it had regained…
benzinga.com Tevogen Reports Advanced Performance For Its AI Platform; Recent Testing Of PredicTcell Model Shows Recall Enhancement From 87% To 92%, Improved Precision From 40% To 48% Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.Tevogen.AI was built to…
benzinga.com BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading…- benzinga.com Tevogen Names Leadership Team For Diversified Growth Strategy Targeting Additional $50M In Annual Revenue By Q2 2026 End Leadership Designations:Digital Health: Arpita Patel and Wojtek StobinskiGenerics: Sadiq Khan and David BankoContract Research: William KeaneBiotech: Lori GrossoArtificial Intelligence: Mittul Mehta
benzinga.com Tevogen Bio Explores Buyout To Boost Generics Platform Tevogen stock swings after Apozeal acquisition talks and a 50-for-1 reverse split as TVGN trades near lows.
benzinga.com Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording gains include DAWN, BATL, RCAT, and SWBI.- benzinga.com Tevogen Bio Holdings Signs Letter Of Intent To Evaluate Potential Acquisition Of Apozeal Pharmaceutical If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including:11 FDA-approved Abbreviated New Drug Application (ANDA) products for the…
- benzinga.com UPDATE: Tevogen Bio Holdings Approves 1-For-50 Reverse Stock Split Effective March 6, 2026 Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors (the "Board") has approved a reverse stock split of its common stock at a ratio of 50 for…
benzinga.com D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $2 D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and lowers the price target from $5 to $2.
benzinga.com Tevogen Strikes Letter Of Intent To Mull Potential Takeover Of Unnamed Contract Research Organization Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential…
benzinga.com Tevogen Signs Non-Exclusive, Non-Binding LOI To Evaluate Potential Transaction With Sciometrix To Augment Capabilities And Transition Into Revenue‑Generating Healthcare Enterprise Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential transaction with…- benzinga.com Tevogen Evaluates Potential One-Time Special Cash Dividend, Subject To Future Financial Milestones Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Tevogen Reports 2025 Milestones, Expands ExacTcell Platform And Multi-Indication CTL Pipeline; Advances In-House GMP Manufacturing Capabilities Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today…
- benzinga.com Tevogen Provided Updates At J.P. Morgan Healthcare Conference Pipeline Expansion Across Multiple Indications:Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions,…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - benzinga.com D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5 D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and lowers the price target from $10 to $5.
- benzinga.com Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibility This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk…
benzinga.com Tevogen Clarifies GAAP-Reported Deficit, Plans Non-GAAP Metrics Disclosure Post Q3 2025 Filing Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP accounting standards in recent…- benzinga.com Tevogen Intends To Collaborate With Government Initiatives, Long COVID Patient Organizations, And Major Healthcare Providers To Expedite Development Of TVGN 489; Establishes A Dedicated Communication Channel For Long COVID Updates At longCOVID@tevogen.com Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of…
- benzinga.com Tevogen Bio Announces Progress On Its PredicTcell Platform Which Uses Advanced Machine Learning And Transformer-Based Models To Accelerate Precision Immunotherapy Development Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designe
- benzinga.com Tevogen Highlights Potential Of Precision T Cell Therapy TVGN 489 To Target Persistent Viral Reservoirs In Long COVID Treatment Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its…
- benzinga.com Tevogen Bio Estimates TVGN 116 Cumulative 5-Yr Top-Line Revenue To Be ~$6.5B; Risk Adjusted Net Present Value For TVGN 116 Is Estimated To Exceed ~$325M In US Alone Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 116, for liver cancer prevention with…
- benzinga.com Tevogen Projects $3.5B Revenue For EBV-Targeting Therapy TVGN 930, With rNPV Exceeding $250M In U.S. Rare Disease Market The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be…
- benzinga.com D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and maintains $10 price target.
- benzinga.com Tevogen Highlights Clinical Data For TVGN 489, A T Cell Therapy Targeting COVID-19 In Immunocompromised Patients Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest…
- benzinga.com Tevogen Reports 24% Rise In Institutional Ownership In Q2 2025, Led By Morgan Stanley And BlackRock Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional…
- benzinga.com Tevogen Bio Secures Up To $50M In Financing Following $94.9M Liability Elimination; Formalizes Agreement First Announced May 2024 Includes $36 million line of credit and potential $14 million private placementWARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a…
- benzinga.com D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and maintains $10 price target.
- benzinga.com Tevogen Bio Highlights Undervalued Intangible Assets, Citing Proprietary IP, AI Platforms And 74% Insider Ownership Tevogen Bio Holdings Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO."Tevogen is an asset-rich enterprise, and we…
- benzinga.com UPDATE: Tevogen Bio Forecasts $1B Launch-Year Revenue, Sees $18B–$22B Over 5 Years, Driven By PASC Treatment And Oncology Pipeline Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion…
- benzinga.com Tevogen Bio Announces $1B Revenue Forecast For The Launch Year Of Its Oncology Pipeline, With A 5-year Cumulative Projection Between $10B And $14B Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat…
- benzinga.com Tevogen Reports Institutional Ownership Jumps 60% In Q1; Vanguard And BlackRock Boost Holdings By 151% Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional…
- benzinga.com D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and maintains $10 price target.
- benzinga.com Tevogen's Tevogen.AI Expands Collaboration With Microsoft And Databricks, To Build The Beta Version Of Its Foundational PredicTcell Model; Tevogen.AI To Explore External Market Opportunities As A Potential Revenue Source; Beta Version To Incorporate Oncology Targets, Enhancing The Accuracy And Diversity Of The Predictcell Model And Potentially Accelerating Cancer Immunotherapy Development WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding…
- benzinga.com D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and maintains $10 price target.